Phil Nadeau

Stock Analyst at TD Cowen

(2.11)
# 1027
Out of 5,270 analysts
32
Total ratings
47.37%
Success rate
41.36%
Average return
19 Stocks
Name Action Price Target Current % Upside Ratings Updated
Kura Oncology
Reiterates: Buy
n/a
n/a n/a 1 Nov 21, 2024
Syros Pharmaceutical...
Downgrades: Hold
n/a
n/a n/a 1 Nov 13, 2024
Rhythm Pharmaceutica...
Maintains: Strong Buy
55 65
52.36 24.14% 2 Nov 6, 2024
Biogen
Maintains: Buy
300 275
141.77 93.98% 6 Oct 31, 2024
Biomarin Pharmaceuti...
Maintains: Buy
125 120
71.05 68.9% 1 Aug 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
450 500
483.3 3.46% 7 Jul 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
n/a
n/a n/a 1 Mar 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 2 Feb 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 1 Oct 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 1 Oct 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
n/a
n/a n/a 1 Jul 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
n/a
n/a n/a 1 Nov 23, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
n/a
n/a n/a 1 Aug 23, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
n/a
n/a n/a 1 Jul 13, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
n/a
n/a n/a 1 Aug 18, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
n/a
n/a n/a 1 Jul 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
n/a
n/a n/a 1 Jul 16, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
n/a
n/a n/a 1 Apr 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
15
n/a n/a 1 May 26, 2017